Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380413 | 1.00 | PPARA (0.49) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL7338978 | 0.89 | SLC1A1 (0.54) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL2584804 | 0.89 | SLC1A1 (0.54) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL4220523 | 0.89 | SLC1A1 (0.54) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL11725850 | 0.88 | LTA4H (0.43) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL8148827 | 0.87 | LTA4H (0.47) | PPARASLC1A1CTSSPPARGLTA4H | |
| SCHEMBL11387995 | 0.83 | SLC7A5 (0.51) | SLC1A1CTSSLTA4HSLC7A5 | |
| SCHEMBL28119342 | 0.81 | LTA4H (0.52) | SLC1A1LTA4HSLC7A5SYKL3MBTL1 | |
| SCHEMBL28119343 | 0.81 | LTA4H (0.52) | SLC1A1LTA4HSLC7A5SYKL3MBTL1 | |
| SCHEMBL16200527 | 0.80 | SLC1A1 (0.59) | SLC1A1SLC7A5CA1TACR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1112071-A4 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1112071-A1 | GROWTH HORMONE SECRETAGOGUES | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-4507232-A | Peptide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1985-03-26 | — | — | US | disclosed |
| US-4346078-A | Novel anticoagulant agmatine derivatives and process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | PPARA 1477/4885SLC1A1 2304/4885CTSS 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.